News

This multi-year deal builds on the ongoing collaboration with AstraZeneca announced in June last year, to include the development of small molecule inhibitors targeting a second cancer-related epigenetic

Statera Biopharma president and CEO Michael K Handley said: “The strategic partnership with Lay Sciences has the potential to produce near term revenue. “The agreement allows Statera the

Additionally, the FDA’s Division of Neurology I granted its request for a pre-IND meeting for discussing a development path for elamipretide along with products within the approved exon-skipping

The company focuses on transforming the treatment of T Cell-mediated pathologies. New investors, Eli Lilly and Company and Sound Bioventures, took part in the financing round along with

The financing round saw participation from other new investors Pavilion Capital, Section 32, Invus and LifeSci Venture Partners. All of the Series A investors of Moma including Third

Under the agreement terms, Arvinas will leverage the Gemini Virtual Patient models of GNS to gain better understanding of the biology of the underlying disease. Arvinas will understand

The company will use these funds to expedite IN10018’s clinical trials that are currently underway for several types of cancer in the US as well as China, including

These patients have inadequate response to corticosteroids or other systemic therapies. Jakavi, an oral JAK 1 and JAK 2 tyrosine kinases inhibitor, was licensed by Novartis from Incyte

Other new investors Alpha Wave Ventures, NexPoint also participated in the round along with existing investors Morningside Ventures, Seligman Investments, and Tao Capital Partners. Apnimed will use the